LOGIN  |  REGISTER
Cue Biopharma

Latest Diagnostics & Research News

PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

January 14
Last Trade: 1.82 -0.20 -9.70

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics. The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic causes of rare diseases,...Read more


Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025

January 14
Last Trade: 144.16 -0.06 -0.04

SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2024 and preliminary outlook for fiscal year 2025 ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). The webcast can be accessed through...Read more


PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

January 14
Last Trade: 1.82 -0.20 -9.70

Commenced shipment of the Vega™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio® system MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2024 and full year 2024 of...Read more


Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care

January 14
Last Trade: 32.92 0.58 1.79

CHICAGO / Jan 14, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel...Read more


DarioHealth Expands GLP-1 Solution with Prescribing Capabilities through Collaboration with MediOrbis, Targeting Employers and Direct-to-Consumer Markets

January 14
Last Trade: 0.88 0.09 11.34

New collaboration enhances Dario's comprehensive GLP-1 offering with virtual physician management to meet growing demand from employers covering weight-loss medications, opening new revenue streams in direct-to-consumer and pharma channels NEW YORK, Jan. 14, 2025 /PRNewswire/ -- January 14, 2025 -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a...Read more


ICON Issues Financial Guidance for Full Year 2025

January 14
Last Trade: 203.36 -14.63 -6.71

Highlights Full year 2025 revenue guidance in the range of $8,050 - $8,650 million; midpoint of $8,350 million representing growth of approximately 1% over full year 2024 revenue guidance midpoint. Full year 2025 adjusted earnings per share* guidance in the range of $13.00 - $15.00; midpoint of $14.00, flat over full year 2024 adjusted earnings per share guidance midpoint. With respect to full year 2024, the company reaffirmed its...Read more


Bionano Genomics Announces Use of OGM in Preimplantation Genetic Testing as Part of Successful Live Birth to a Couple Experiencing Recurrent Pregnancy Loss

January 14
Last Trade: 0.21 -0.02 -8.03

OGM uniquely identified a complex chromosomal rearrangement missed by classical cytogenetics, helping clinical researchers apply targeted screening to select the most fit embryos for transfer Following in-vitro fertilization, preimplantation genetic testing and selection of fit embryos, a healthy baby was born to a couple that had previously experienced years of recurrent pregnancy loss SAN DIEGO, Jan. 14, 2025 (GLOBE NEWSWIRE) --...Read more


Sotera Health Chairman and CEO Presents at 43rd Annual J.P. Morgan Healthcare Conference

January 14
Last Trade: 12.72 -0.38 -2.90

CLEVELAND, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is presenting today at the 43rd Annual J.P. Morgan Healthcare Conference. During the presentation, Chairman and CEO Michael B. Petras, Jr. will be providing an update on Sotera...Read more


QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024

January 13
Last Trade: 41.81 -2.80 -6.28

Top-line Results In Line with Expectations; Company Expects to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 SAN DIEGO / Jan 13, 2025 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited...Read more


IQVIA and NVIDIA Collaborate to Transform Healthcare and Life Sciences Through Advanced Agentic AI Solutions

January 13
Last Trade: 199.41 -5.23 -2.56

RESEARCH TRIANGLE PARK, N.C. / Jan 13, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences. The healthcare and life sciences industries generate vast amounts of data, representing significant potential for AI-powered...Read more


Illumina and NVIDIA collaborate to decode biology and propel precision health

January 13
Last Trade: 144.16 -0.06 -0.04

Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in...Read more


Tempus AI Announces Its First-Ever, Whole-Genome Sequencing Assay, xH

January 13
Last Trade: 32.92 0.58 1.79

CHICAGO / Jan 13, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xH. This test marks Tempus’ first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with detection of all clinically-relevant variants and advancing the...Read more


Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2024 Results

January 13
Last Trade: 0.21 -0.02 -8.03

Preliminary Q4 2024 revenue expected to be between $7.9 and $8.1 million, which would represent an estimated decrease of approximately 25% over Q4 2023 due primarily to discontinuation of clinical service products in 2024 Installed base of optical genome mapping (OGM) systems reached an estimated 371 as of YE 2024, which is an increase of 14% over the 326 installed OGM systems as of YE 2023 Preliminary number of nanochannel array...Read more


Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

January 13
Last Trade: 120.70 -2.00 -1.63

WALTHAM, Mass. & SAN DIEGO / Jan 13, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introduction of an automated...Read more


Tempus AI Announces Preliminary Fourth Quarter and Full Year 2024 Results

January 13
Last Trade: 32.92 0.58 1.79

CHICAGO / Jan 13, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Select, Preliminary, Unaudited Financial Results Revenue of approximately $693 million, representing approximately 30% growth...Read more


Quantum-Si Launches Platinum® Pro: The End-to-End Solution for Deeper Insights in Proteomics

January 13
Last Trade: 2.05 0.12 5.96

BRANFORD, Conn. / Jan 13, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the launch of Platinum® Pro, its latest benchtop sequencer that sets a new standard in protein analysis. Designed to redefine efficiency and versatility in proteomics research, Platinum Pro is now available for ordering. Platinum Pro delivers a comprehensive solution for...Read more


Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

January 13
Last Trade: 178.11 -12.03 -6.33

WILMINGTON, Mass. / Jan 13, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link...Read more


Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook

January 13
Last Trade: 78.20 -1.64 -2.05

SAN DIEGO / Jan 13, 2025 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the fourth quarter of 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4% over the fourth quarter of 2023. International revenue is expected to be approximately $310...Read more


Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results

January 13
Last Trade: 37.30 -0.80 -2.10

Full year revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds PALO ALTO, Calif. / Jan 13, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. Fourth quarter 2024 preliminary unaudited financial results For the three-month period ended December...Read more


Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

January 13
Last Trade: 1.99 -0.07 -3.40

 Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m. PT. SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and...Read more


CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results

January 13
Last Trade: 24.18 -0.89 -3.55

Fourth Quarter Revenue is Expected to Increase 30% Year-Over-Year Expects Full Year 2024 Revenue of $332 Million to $333 Million BRISBANE, Calif. / Jan 13, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Financial Results Revenue is expected to be...Read more


MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance

January 13
Last Trade: 2.01 0.01 0.50

IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, representing year-over-year growth of 28% for both periods....Read more


Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples

January 13
Last Trade: 144.16 -0.06 -0.04

Study will generate a key reference data set with Illumina Protein Prep solution SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The pilot program is based on...Read more


Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market

January 13
Last Trade: 93.37 -1.28 -1.35

Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s Disease Advances Lantheus’ radiopharmaceutical leadership with addition of Alzheimer’s radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&D capabilities Transaction expected to be accretive to adjusted EPS within the first 12 months Company...Read more


Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

January 12
Last Trade: 167.20 -2.11 -1.25

2024 revenues are expected to increase by approximately 56% compared to 2023, which is approximately $53 million above top end of financial outlook Additional business updates to be presented by Natera at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 AUSTIN, Texas / Jan 12, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today released preliminary...Read more


Exact Sciences Announces Preliminary Fourth Quarter 2024 Results

January 12
Last Trade: 54.99 -3.52 -6.02

Highlighted announcements: Expects total fourth quarter revenue of $713 million, an increase of 10% compared to the fourth quarter of 2023, with Screening revenue of $553 million and Precision Oncology revenue of $161 million Anticipates total full-year 2024 revenue of $2.76 billion, an increase of 10% compared to full-year 2023 Plans to launch three new cancer tests in 2025: Cologuard PlusTM, next-generation colorectal cancer...Read more


Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

January 12
Last Trade: 24.46 -1.69 -6.46

2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023 Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities expected to be approximately $293 million FRIENDSWOOD, Texas / Jan 12, 2025 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health...Read more


Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance

January 12
Last Trade: 120.70 -2.00 -1.63

WALTHAM, Mass. / Jan 12, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference...Read more


Qiagen to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

January 12
Last Trade: 45.45 -0.55 -1.20

Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS Return of up to $300 million – maximum approved by shareholders – set to be completed in late January 2025 Builds on approximately $300 million returned to shareholders in early 2024 as part of commitment to return at least $1 billion through end 2028 VENLO,...Read more


Exagen Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

January 12
Last Trade: 3.13 0.01 0.35

New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn CARLSBAD, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced it has received conditional approval from the New York State Department of Health...Read more


Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

January 10
Last Trade: 1.12 -0.01 -0.88

TUCSON, Ariz., Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2024. "During the fourth quarter, we continued our momentum across...Read more


Applied DNA Sciences Completes Buildout of GMP Facility for LineaDNA IVT Templates

January 10
Last Trade: 0.19 -0.0044 -2.28

Signals Start of New Commercialization Phase for LineaRx Subsidiary Company Negotiating GMP Supply Agreement Company Reaffirms Strategic Restructuring Timeline STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing...Read more


Revvity Announces FDA Clearance for First Automated Free Testosterone Test

January 10
Last Trade: 120.70 -2.00 -1.63

WALTHAM, Mass. / Jan 10, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement...Read more


NeoGenomics Announces Chief Executive Officer Succession

January 10
Last Trade: 12.52 -0.11 -0.87

Chris Smith to retire effective April 1, 2025; Board Member Tony Zook named incoming CEO Company reaffirms Fiscal 2024 financial guidance FT. MYERS, Fla. / Jan 10, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook, an...Read more


Neogen Announces Preliminary¹ Second-Quarter 2025 Results

January 10
Last Trade: 11.82 -0.82 -6.49

Revenue of $231.3 million. Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share. Adjusted Net Income2 of $24.4 million; $0.11 per diluted share. Adjusted EBITDA2 of $51.4 million. Updating full-year guidance. LANSING, Mich., Jan. 10, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today the preliminary results of the second quarter ended November 30, 2024. "The second...Read more


PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

January 10
Last Trade: 1.82 -0.20 -9.70

MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform and PacBio’s HiFi sequencing technology. By combining Intus Bio’s patented strain-level resolution assay and AI-powered...Read more


Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

January 10
Last Trade: 1.20 -0.05 -3.63

LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2024 (fiscal 2024). The financial results included in this release pertaining to the fourth quarter and fiscal 2024 are preliminary, unaudited, and subject to final review and adjustment. Preliminary Unaudited Fourth...Read more


QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

January 10
Last Trade: 45.45 -0.55 -1.20

QIAcuity digital PCR now offers ability for simultaneous detection of up to 12 targets from one biological sample, a more than two-fold increase from prior capability for up to five targets No instrument hardware changes required for upgraded capability thanks to new QIAcuity Software 3.1 update and launch of QIAcuity High Multiplex Probe PCR Kit New QIAcuity digital PCR capabilities helps make lab work more productive and...Read more


Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

January 10
Last Trade: 0.59 -0.05 -7.17

Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations. Mr. Buhle has over 25 years of experience driving commercial growth and new...Read more


Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

January 9
Last Trade: 32.92 0.58 1.79

CHICAGO / Jan 09, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient...Read more


Thermo Fisher Scientific’s Olink Platform Selected for World’s Largest Human Proteome Study

January 9
Last Trade: 558.10 2.58 0.46

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery WALTHAM, Mass. / Jan 09, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support the world’s largest human...Read more


Qiagen secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

January 9
Last Trade: 45.45 -0.55 -1.20

New QIAstat-Dx Gastrointestinal Panel 2 Mini B&V (bacterial and viral) tailored to provide fast answers for outpatient diagnosis of gastrointestinal conditions QIAGEN the first to offer both comprehensive and targeted syndromic gastrointestinal panels, giving clinicians unmatched flexibility to optimize diagnostics for individual patients QIAstat-Dx Rise higher-capacity instrument version to be submitted in early 2025 for U.S....Read more


Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening

January 9
Last Trade: 0.17 0.00 0.00

A screening indication for women with dense breast tissue adjunctive to 3D mammography increases the market size for annual IzoView scans by over 800%1 for initial approval and product launch Regulatory strategy responds to the "urgent call2" from the U.S. Preventative Services Task Force for solutions to finding breast cancers earlier in women with dense breast tissue Comprehensive filing includes patient acquisition and...Read more


Tempus AI Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

January 8
Last Trade: 32.92 0.58 1.79

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient biomarkers...Read more


Quantum-Si’s New Preprint Showcases Protein Barcoding as a Powerful Tool for Transforming Proteomics

January 8
Last Trade: 2.05 0.12 5.96

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the release of its latest preprint titled “Protein Barcoding and Next-Generation Protein Sequencing for Multiplexed Protein Selection, Analysis, and Tracking.” This study highlights the potential of integrating Quantum-Si’s benchtop Platinum® instrument with an...Read more


Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 13.64 -0.64 -4.48

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor relations section of Myriad’s website at...Read more


23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology

January 8
Last Trade: 3.56 -0.09 -2.34

SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today announced the launch of Discover23®, a new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe research cohort through a Trusted Research Environment (TRE) developed by Lifebit, a technology company trusted by some of the world’s leading...Read more


Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine

January 8
Last Trade: 1.99 -0.07 -3.40

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study published in the current issue of Nature Medicine titled “Proteomic changes upon treatment with semaglutide in individuals with obesity”. Conducted by a team of researchers from Novo Nordisk A/S and collaborators, this seminal paper...Read more


RadNet to Present at the 43rd Annual J.P. Morgan Healthcare Conference January 15th, 2025

January 8
Last Trade: 66.51 -0.08 -0.12

LOS ANGELES, Jan. 08, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, Mark Stolper, Executive Vice President and Chief Financial Officer and Dr. Gregory Sorensen, Executive Vice President and...Read more


Quest Diagnostics Names Adrienne Brott Senior Vice President and Chief Quality and Regulatory Affairs Officer

January 8
Last Trade: 151.29 -2.73 -1.77

Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team SECAUCUS, N.J., Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Adrienne L. Brott, an accomplished quality and regulatory affairs healthcare leader, has been named senior vice president and chief quality and regulatory affairs...Read more


Sotera Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 12.72 -0.38 -2.90

CLEVELAND, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 11:15 a.m. Eastern...Read more


Illumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applications

January 7
Last Trade: 144.16 -0.06 -0.04

Software upgrade advances complete workflow solutions New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X, and enable newly released Illumina Single-Cell Prep SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell...Read more


T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

January 7
Last Trade: 0.29 -0.03 -9.69

LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 and Recent Commercial Highlights (unaudited) Achieved record product revenues of $2.3...Read more


Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection

January 7
Last Trade: 37.30 -0.80 -2.10

Guardant Health Shield multi-cancer detection test selected on basis of strong performance in predicting presence of cancers and cancer tissue of origin Pilot study by National Cancer Institute’s Cancer Screening Research Network will inform design of future research evaluating use of multi-cancer detection blood tests to screen for cancer PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision...Read more


OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck

January 7
Last Trade: 1.49 -0.04 -2.61

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosis There are no current treatments or vaccines for EBV First participant dosed with novel investigational EBV vaccine targeting multiple viral proteins in Phase I study WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), announces dosing of the first...Read more


Bionano Genomics Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic Leukemia

January 7
Last Trade: 0.21 -0.02 -8.03

A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was missed by karyotyping and non-informative by FISH, which they classified as a PML::RARA fusion known to occur in acute promyelocytic leukemia (APL) The researchers reported that APL, an aggressive subtype of acute myelogenous leukemia (AML), responds well to treatment with all-trans retinoic...Read more


MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

January 7
Last Trade: 13.64 -0.64 -4.48

HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research...Read more


Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

January 7
Last Trade: 1.20 -0.05 -3.63

LOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical validation study was published in CHEST Pulmonary Journal that reaffirms the previously established performance of the Nodify CDT® blood-based lung nodule test. Clinical data is one of the foundational pillars driving the success of Biodesix through...Read more


Danaher to Present at J.P. Morgan Healthcare Conference

January 6
Last Trade: 235.16 -4.72 -1.97

WASHINGTON, Jan. 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025 at 11:15 a.m. PT. The event will be simultaneously webcast and can be accessed on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events...Read more


Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test

January 6
Last Trade: 24.46 -1.69 -6.46

With this approval, all of the tests in Castle’s dermatology, gastroenterology and ophthalmology portfolios, as well as its clinical laboratories in Phoenix and Pittsburgh, are now approved by the state of New York FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York...Read more


Sera Prognostics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6
Last Trade: 6.34 0.01 0.16

SALT LAKE CITY, Jan. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco. Zhenya Lindgardt, President and CEO, will...Read more


Bionano Genomics Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

January 6
Last Trade: 0.21 -0.02 -8.03

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering...Read more


Sotera Health Appoints Vincent K. Petrella as Lead Independent Director

January 6
Last Trade: 12.72 -0.38 -2.90

CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company’s Board of Directors since...Read more


Bionano Genomics Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

January 3
Last Trade: 0.21 -0.02 -8.03

SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per...Read more


Thermo Fisher Scientific to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

January 3
Last Trade: 558.10 2.58 0.46

WALTHAM, Mass. / Jan 03, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About...Read more


PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 2
Last Trade: 1.82 -0.20 -9.70

MENLO PARK, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, California. A live webcast of the event can be accessed at the company’s investors page at...Read more


QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 31
Last Trade: 41.81 -2.80 -6.28

SAN DIEGO / Dec 31, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. The Company’s presentation is scheduled for Monday, January 13, 2025 at 7:30...Read more


Inotiv Completes Equity Offering for Net Proceeds of Approximately $3.6 Million

December 30
Last Trade: 4.19 -0.03 -0.71

WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised an additional $3.6 million in net proceeds from the optional shares in connection with its previously announced underwritten...Read more


Bionano Genomics Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis

December 23
Last Trade: 0.21 -0.02 -8.03

In the largest study to date of bone and soft tissue tumors, OGM detected 100% of the variants found by multiple standard techniques, including karyotyping, fluorescent in-situ hybridization (FISH) & gene fusion assays OGM was also more sensitive, including detection of diagnostic or pathogenic variants missed by karyotype in 74% (14/19) of cases that failed or were negative by karyotyping When OGM results and next-generation...Read more


Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test

December 23
Last Trade: 24.46 -1.69 -6.46

Assuming successful validation, the Company currently expects to launch the pipeline test by the end of 2025 FRIENDSWOOD, Texas / Dec 23, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis (AD) who are seeking...Read more


Inotiv Completes Equity Offering for Net Proceeds of Approximately $24.0 Million

December 23
Last Trade: 4.19 -0.03 -0.71

WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised approximately $24.0 million in net proceeds from its underwritten public offering of 6,000,000 common shares at a price to the...Read more


Telo Genomics Closes Oversubscribed $2.5 Million Private Placement

December 23
Last Trade: 0.12 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - December 23, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce that, further to its news release dated December 12, 2024, it has closed an over-subscribed, non-brokered private placement of 25,459,000 units ("Units") at a price of $0.10 per Unit for gross proceeds of $2,545,900 (the "Offering"). Each Unit consists of one common share of...Read more


iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens

December 20
Last Trade: 2.73 0.05 1.87

Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025, expanding services to procure high demand cancer biospecimens, enhancing its ability to support groundbreaking cancer research worldwide. The demand for cancer tissue continues to grow as cancer remains a significant area of focus in medical...Read more


Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care

December 20
Last Trade: 37.30 -0.80 -2.10

PALO ALTO, Calif. & TAMPA, Fla. / Dec 20, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network. Recognizing the evolving...Read more


Quantum-Si’s New Preprint Showcases Advances in Protein Variant Detection using ProteoVue™ Software with Next-Generation Protein Sequencing™

December 20
Last Trade: 2.05 0.12 5.96

Announces early access availability of ProteoVue Software ProteoVue is part of broader set of innovation initiatives, including the Company’s recently announced collaboration with NVIDIA, to leverage AI to enhance sequencing performance BRANFORD, Conn. / Dec 20, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a new paper that was...Read more


Prenetics Global IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

December 19
Last Trade: 5.94 0.51 9.39

Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness IM8, a New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com CHARLOTTE, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics’ (NASDAQ:PRE) IM8, a premium supplements brand focused on science-driven health solutions, is excited to announce a collaboration through a know-how agreement with Mayo Clinic to...Read more


Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference

December 19
Last Trade: 43.30 -0.28 -0.64

SOUTH SAN FRANCISCO / Dec 19, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. Pacific Time in San Francisco, California. The...Read more


Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

December 19
Last Trade: 4.86 0.19 4.07

BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz Biomed’s NextGen screening test for colorectal...Read more


Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 19
Last Trade: 1.99 -0.07 -3.40

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference taking place on January 13th - 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s corporate presentation will be held on January 16th, 2024, at 9:45 a.m. PT. A live...Read more


BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP

December 19
Last Trade: 0.42 0.00 0.00

VANCOUVER, BC / ACCESSWIRE / December 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the expansion of its intellectual property portfolio with the filing of new international patents for sublingual delivery technologies targeting autoimmune neurodegenerative diseases. Building upon the positive...Read more


Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV

December 18
Last Trade: 0.79 -0.03 -3.78

DUBLIN, Ireland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an important update on its Comprehensive Transformation Plan, which includes the transfer of manufacturing of both TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturing partner. Trinity...Read more


Applied DNA Sciences Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

December 18
Last Trade: 0.19 -0.0044 -2.28

Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies  STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial...Read more


T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

December 18
Last Trade: 0.29 -0.03 -9.69

LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrument sale demonstrates...Read more


Tempus AI Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions

December 18
Last Trade: 32.92 0.58 1.79

CHICAGO / Dec 18, 2024 / Business Wire / Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions, a laboratory benefit manager. As part of the agreement with Avalon, Tempus is a participating provider...Read more


Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer

December 18
Last Trade: 37.30 -0.80 -2.10

PALO ALTO, Calif. / Dec 18, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360® CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 while sparing epidermal...Read more


ICON Announces Appointment of Chief Operating Officer

December 18
Last Trade: 203.36 -14.63 -6.71

DUBLIN / Dec 18, 2024 / Business Wire / ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and...Read more


Dexcom Launches the First Generative AI Platform in Glucose Biosensing

December 17
Last Trade: 78.20 -1.64 -2.05

Dexcom builds on its history of first-in-market innovations with the launch of its new groundbreaking GenAI platform Dexcom GenAI-enabled technology will leverage Google Cloud’s Vertex AI platform and Gemini models and will initially enhance Stelo’s Weekly Insights feature by providing users with more personalized content based on glucose levels, activity and sleep Proprietary platform lays foundation for future GenAI advancements...Read more


Neogen Launches Petrifilm® Bacillus cereus Count Plate to Enhance Food Safety Testing Efficiency

December 17
Last Trade: 11.82 -0.82 -6.49

LANSING, Mich., Dec. 17, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, has introduced a new addition to its Petrifilm® product line, the Neogen Petrifilm Bacillus cereus Count Plate. This innovative new solution offers food safety professionals a simple, reliable, and efficient method for testing for Bacillus cereus, a persistent threat with potentially deadly consequences. The...Read more


New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus AI ECG-AF Device

December 17
Last Trade: 32.92 0.58 1.79

New decision establishes reimbursement for the clinical use of Tempus ECG-AF, reducing the financial burden of using AI to improve early detection of atrial fibrillation CHICAGO / Dec 17, 2024 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS)...Read more


Revvity to Present at J.P. Morgan Healthcare Conference

December 17
Last Trade: 120.70 -2.00 -1.63

WALTHAM, Mass. / Dec 17, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities. To access the presentation, a live audio webcast will be available via this page. A replay of the presentation will...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE